Older American women on Medicare will greatly benefit from the proposed White House deal starting around the middle of next ...

One in eight U.S. adults now take GLP-1 drugs, but many struggle to afford them • Cost is a leading reason people stop using ...

Trump's deal slashes GLP-1 drug costs for Medicare beneficiaries and others, unlocking coverage for millions with obesity and ...

In a landmark deal announced last week, President Donald Trump negotiated dramatically lower costs for weight-loss drugs produced by pharmaceutical giants Eli Lilly and Novo Nordisk, which could ...

Direct-to-consumer sales of medications often mean lower prices and more convenience for patients.

This comes during a time when when Eli Lilly and Novo Nordisk have been garnering momentum—last week, the FDA added ...

One of the biggest gripes around weight loss medications like Wegovy and Zepbound is the high price tag. At $1,000 or more a ...

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1,350 a month. Under the ...

For a president who wants to project vigor and command at all times, Donald Trump made the worst possible spectacle of himself in the Oval Office last Thursday.

In a landmark deal announced Thursday, President Donald Trump negotiated dramatically lower costs for weight-loss drugs produced by pharmaceutical giants Eli Lilly and Novo Nordisk, which could benefi ...

P opular weight-loss drugs known as GLP-1s could soon become more affordable for Americans. On Thursday, the Trump ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...